BI 2536

Catalog No.S1109

Molecular Weight(MW): 521.66

BI2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM in a cell-free assay. It shows 4- and 11-fold greater selectivity against Plk2 and Plk3. Phase 2.

Cited by 102 Publications

Science, 2019, 364(6447)

PubMed: 31249032 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Nature, 2017, 548(7668):466-470

PubMed: 28759889 ( click the link to review the publication )

Cancer Discov, 2014, 4(11):1281-9

PubMed: 25107667 ( click the link to review the publication )

Cell, 2011, 4(10):1087-96

PubMed: 22078882 ( click the link to review the publication )

Cell Syst, 2019, 8(2):163-167

PubMed: 30797774 ( click the link to review the publication )

Cell Syst, 2019, 9(1):74-92.e8

PubMed: 31302152 ( click the link to review the publication )

EBioMedicine, 2019, 41:244-255

PubMed: 30876762 ( click the link to review the publication )

Cell Death Dis, 2019, 10(6):385

PubMed: 31097686 ( click the link to review the publication )

Ther Adv Med Oncol, 2019, 11:1758835919846375

PubMed: 31156720 ( click the link to review the publication )

J Mol Cell Biol, 2019, 10.1093/jmcb/mjz051

PubMed: 31174204 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(9):1615-1627

PubMed: 31227645 ( click the link to review the publication )

FEBS J, 2019, 286(5):963-974

PubMed: 30600590 ( click the link to review the publication )

Lab Invest, 2019, 99(9):1275-1286

PubMed: 30996295 ( click the link to review the publication )

Theranostics, 2018, 8(10):2884-2895

PubMed: 29774081 ( click the link to review the publication )

Sci Signal, 2018, 11(549)

PubMed: 30254057 ( click the link to review the publication )

Sci Signal, 2018, 11(530)

PubMed: 29764992 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(7):1554-1565

PubMed: 29716963 ( click the link to review the publication )

Mol Cell Proteomics, 2018, 17(12):2434-2447

PubMed: 30217950 ( click the link to review the publication )

J Cell Mol Med, 2018, 22(11):5300-5310

PubMed: 30133120 ( click the link to review the publication )

Transl Oncol, 2018, 11(4):852-863

PubMed: 29753186 ( click the link to review the publication )

Mol Cell, 2017, 68(1):210-223e6

PubMed: 28985505 ( click the link to review the publication )
FASEB J, 2017, 32(2):625-638

PubMed: 28970258 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 43(2):431-444

PubMed: 28922657 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(1):3-15

PubMed: 27760837 ( click the link to review the publication )

FEBS J, 2017, 284(23):4035-4050

PubMed: 28985013 ( click the link to review the publication )

Cell Signal, 2017, 39:74-83

PubMed: 28780319 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2017, 313(5):C501-C515

PubMed: 28794108 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 484(4):864-870

PubMed: 28188792 ( click the link to review the publication )

Oncotarget, 2017, 8(23):37633-37645

PubMed: 28430578 ( click the link to review the publication )

Nat Chem Biol, 2016, 10.1038/nchembio.2017

PubMed: 26829474 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Nat Commun, 2016, 7:10818

PubMed: 26912231 ( click the link to review the publication )

J Virol, 2016, 90(6):2794-805

PubMed: 26719254 ( click the link to review the publication )

Sci Rep, 2016, 6:19567

PubMed: 26777522 ( click the link to review the publication )

J Biol Chem, 2016, 10.1074/jbc.M116.722751

PubMed: 27226586 ( click the link to review the publication )

J Biol Chem, 2016, 10.1074/jbc.M115.712745

PubMed: 27325694 ( click the link to review the publication )

J Biol Chem, 2016, 291(20):10904-15

PubMed: 27002159 ( click the link to review the publication )

Cell Cycle, 2016, 15(15):2009-18

PubMed: 27249336 ( click the link to review the publication )

PLoS One, 2016, 11(4):e0153818

PubMed: 27097159 ( click the link to review the publication )

Head Neck, 2016, 10.1002/hed.24349

PubMed: 26713885 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(2):113-22

PubMed: ( click the link to review the publication )

Nat Cell Biol, 2015, 17(2):113-22

PubMed: 25599390 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(1):31-43

PubMed: 25503564 ( click the link to review the publication )

Nat Commun, 2015, 6:8388

PubMed: 26399523 ( click the link to review the publication )

Nat Commun, 2015, 10.1038/ncomms8217

PubMed: 26147444 ( click the link to review the publication )
Nat Commun, 2015, 6:6891

PubMed: 25922916 ( click the link to review the publication )

Cancer Res, 2015, 75(2):405-14

PubMed: 25480943 ( click the link to review the publication )

J Control Release, 2015, 204:20-29

PubMed: ( click the link to review the publication )

Cancer Lett, 2015, 357(2):591-601

PubMed: 25524551 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):527-43

PubMed: 25454348 ( click the link to review the publication )

Mol Cell Proteomics, 2015, 14(4):946-60

PubMed: 25659891 ( click the link to review the publication )

J Neurochem, 2015, 10.1111/jnc.13085

PubMed: 25727910 ( click the link to review the publication )

J Biol Chem, 2015, 290(5):3033-44

PubMed: 25505268 ( click the link to review the publication )

Mol Biol Cell, 2015, 26(3):440-52

PubMed: ( click the link to review the publication )

Cell Cycle, 2015, 14(2):219-31

PubMed: 25607646 ( click the link to review the publication )

Oncotarget, 2015, 6(4):2315-30

PubMed: 25537513 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5275-91

PubMed: 25779659 ( click the link to review the publication )

Oncotarget, 2015, 6(4):2315-30

PubMed: 25537513 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(12):3211-21

PubMed: 24771642 ( click the link to review the publication )

Cancer Res, 2014, 74(20):5878-90

PubMed: 25125659 ( click the link to review the publication )

ACS Chem Biol, 2014, 9(5):1160-71

PubMed: 24568369 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 13(5):1054-66

PubMed: 24748653 ( click the link to review the publication )

J Biol Chem, 2014, 289(38):26344-56

PubMed: 25100726 ( click the link to review the publication )

J Biol Chem, 2014, 289(18):12313-29

PubMed: 24634213 ( click the link to review the publication )

J Biol Chem, 2014, 289,14066-14074

PubMed: ( click the link to review the publication )

J Biol Chem, 2014, 289(20):14066-74

PubMed: 24706748 ( click the link to review the publication )

Cell Cycle, 2014, 13(2):303-14

PubMed: 24247149 ( click the link to review the publication )

Cell Cycle, 2014, 13(24):3867-77

PubMed: 25558830 ( click the link to review the publication )

Cell Cycle, 2014, 13(14):2248-61

PubMed: 24875404 ( click the link to review the publication )
Biosci Rep, 2014, 34(3)

PubMed: 24844881 ( click the link to review the publication )

PLoS One, 2014, 9(12):e115228

PubMed: 25542032 ( click the link to review the publication )

PLoS One, 2014, 8(10):e77053

PubMed: 24204733 ( click the link to review the publication )

Oncotarget, 2014, 5(3):667-78

PubMed: 24525428 ( click the link to review the publication )

The University of Queensland, 2014, Fawzi Faisal A. Bokhari

PubMed: ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 110(32):13026-31

PubMed: 23878225 ( click the link to review the publication )

Cancer Res, 2013, 73(22):6722-33

PubMed: 24101154 ( click the link to review the publication )

Cancer Res, 2013, 73(2):813-23

PubMed: 23144294 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6310-22

PubMed: 24067506 ( click the link to review the publication )

Oncogene, 2013, 10.1038/onc.2013.518

PubMed: 24317508 ( click the link to review the publication )

Br J Cancer, 2013, 110(2):510-9

PubMed: 24327015 ( click the link to review the publication )

Gynecol Oncol, 2013, 128(3):461-9

PubMed: 23146687 ( click the link to review the publication )

J Biol Chem, 2013, 288(20):14158-69

PubMed: 23504319 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2013, 54(13):8353-63

PubMed: 24366665 ( click the link to review the publication )

Cancer Biol Ther, 2013, 14(5):436-49

PubMed: 23377828 ( click the link to review the publication )

PLoS One, 2013, 8(10):e77390

PubMed: 24155950 ( click the link to review the publication )

J Biomol Screen, 2013, 18(1):54-66

PubMed: 22923784 ( click the link to review the publication )

Biol Open, 2013, 2(5):479-86

PubMed: 23789096 ( click the link to review the publication )

J Biol Chem, 2012, 287(6):4376-85

PubMed: 22184120 ( click the link to review the publication )

J Biol Chem, 2012, 287(21):17088-99

PubMed: 22467873 ( click the link to review the publication )

Cell Cycle, 2012, 11(3):543-53

PubMed: 22262171 ( click the link to review the publication )

PLoS One, 2012, 7(6):e38838

PubMed: 22701722 ( click the link to review the publication )

Biotechniques, 2012, 10.2144/000113866

PubMed: ( click the link to review the publication )

Biotechniques, 2012, 53(1)

PubMed: 26307252 ( click the link to review the publication )
Nat Cell Biol, 2011, 13(10):1265-71

PubMed: 21874008 ( click the link to review the publication )

Cancer Res, 2011, 71(4):1385-95

PubMed: 21303981 ( click the link to review the publication )

Cancer Res, 2011, 71(17):5659-69

PubMed: 21693658 ( click the link to review the publication )

J Cell Biol, 2011, 193(6):1083-99

PubMed: 21646404 ( click the link to review the publication )

Oncogene, 2011, 30(46):4666-77

PubMed: 21602893 ( click the link to review the publication )

J Invest Dermatol, 2011, 131(9):1886-95

PubMed: 21654832 ( click the link to review the publication )

Purity & Quality Control

Choose Selective PLK Inhibitors

Biological Activity

Description

BI2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM in a cell-free assay. It shows 4- and 11-fold greater selectivity against Plk2 and Plk3. Phase 2.

Features

The first potent and selective Plk1 inhibitor that induces all hallmarks of Plk1 inhibition.

Targets

PLK1 ^[1] (Cell-free assay)	PLK2 ^[1] (Cell-free assay)	PLK3 ^[1] (Cell-free assay)
0.83 nM	3.5 nM	9.0 nM

In vitro

BI 2536 blocks the activities of Plk2 and Plk3 to a slightly lesser extent with IC50 of 3.5 nM and 9.0 nM, respectively. In HeLa cells, BI 2536 treatment ranging from 10-100 nM leads to the blocking of the recruitment of γ-tubulin and phosphorylation of Apc6 at mitotic centrosomes, inhibition of cohesin release from chromosome arms, induction of monopolar spindles, as well as a range of other mitotic processes that are known to depend on Plk1. BI 2536 treatment leads to the HeLa cells arrested in G2/M, subsequently a sub-G1 DNA peak indicative of DNA breakdown and apoptosis, and accumulated cleaved PARP p85 fragments in a concentration-dependent manner. BI 2536 inhibits the growth of a panel of 32 human cancer cell lines with EC50 of 2-25 nM, while blocking the proliferation of exponentially growing hTERT-RPE1, human umbilical vein endothelial cells (HUVECs), and normal rat kidney (NRK) cells with EC50 of 12-31 nM. ^[1] Plk1 inhibition by BI 2536 reduces the growth and viability of anaplastic thyroid carcinoma (ATC) cells such as CAL62, OCUT-1, SW1736, 8505C, and ACT-1 with EC50 values of 1.4-5.6 nM. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
PSN1	NVvnVYNPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV\JR\|UxRTBwMEC3O\|Yh\|ryP	MmjUV2FPT0WU
ACN	M4\MOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NE[4UnZKSzVyPUCuNFA5PDNizszN	M1;iW3NCVkeHUh?=
TE-8	MkG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFLw[pVKSzVyPUCuNFA6PDFizszN	MnH2V2FPT0WU
LC-2-ad	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUHJR\|UxRTBwMEGwPVMh\|ryP	M2DFVnNCVkeHUh?=
ALL-PO	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYjJR\|UxRTBwMEGzJO69VQ>?	M1rYcXNCVkeHUh?=
EW-16	Ml\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX3LUnhsUUN3ME2wMlAyOzN4IN88US=>	M2HkfnNCVkeHUh?=
KM12	NFjRZ21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTBwMEGzOFgh\|ryP	MVHTRW5ITVJ?
GI-1	NEG0[YxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2TPO2lEPTB;MD6wNVM5OyEQvF2=	NWfTc2pEW0GQR1XS
LS-411N	NHrlOJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTBwMEG0NFch\|ryP	MUDTRW5ITVJ?
ES8	NXjlWmZVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVjJR\|UxRTBwMEG0PVQh\|ryP	MnHBV2FPT0WU
SNU-C2B	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlrITWM2OD1yLkCxOVI3KM7:TR?=	MnnhV2FPT0WU
CESS	NIDscZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{XjNWlEPTB;MD6wNVYxOiEQvF2=	NWr0XVZ4W0GQR1XS
697	Mnf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFG5XnBKSzVyPUCuNFE3PjhizszN	NXjnZXN3W0GQR1XS
NCI-H1963	NIDmTGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2f5UWlEPTB;MD6wNVY4OyEQvF2=	NGWxSlhUSU6JRWK=
IA-LM	NFntNWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV6yXY9DUUN3ME2wMlAyPjh6IN88US=>	MoexV2FPT0WU
SW954	NEHINFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnvLTWM2OD1yLkCxO\|A2KM7:TR?=	MV3TRW5ITVJ?
RL95-2	MmfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYLLdFc3UUN3ME2wMlAyPzN6IN88US=>	M2q0NXNCVkeHUh?=
LXF-289	NUjiTZA6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYLqSY5QUUN3ME2wMlAyPzdizszN	MYXTRW5ITVJ?
OCUB-M	NHT6fIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTBwMEG4NlYh\|ryP	NU\h[lNNW0GQR1XS
RKO	Mm[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2fBbWlEPTB;MD6wNVk5PyEQvF2=	MnT4V2FPT0WU
LOUCY	NUXMc2ZpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mlv0TWM2OD1yLkCyNFUh\|ryP	NG\mNohUSU6JRWK=
NOS-1	NGK0d4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVzueYFbUUN3ME2wMlAzODl\|IN88US=>	Ml7yV2FPT0WU
A4-Fuk	MlPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUjJR\|UxRTBwMEKyNVgh\|ryP	MVzTRW5ITVJ?
A388	NGm3ZmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUXJR\|UxRTBwMEKyNlch\|ryP	M3;1O3NCVkeHUh?=
TE-9	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVHJN\|ljUUN3ME2wMlAzOjZzIN88US=>	NFLTXHZUSU6JRWK=
KURAMOCHI	M37EVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmiyTWM2OD1yLkCyNlg2KM7:TR?=	Mn3JV2FPT0WU
KALS-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2D4XGlEPTB;MD6wNlM{QCEQvF2=	NFTtbmZUSU6JRWK=
HOP-62	NYrqNGM{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHvP[HZKSzVyPUCuNFI1OiEQvF2=	MVXTRW5ITVJ?
RPMI-8402	NHjZNVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFXUXodKSzVyPUCuNFI2ODhizszN	M4PqeXNCVkeHUh?=
TE-1	NUn2cHZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M37OZWlEPTB;MD6wNlUyOiEQvF2=	NF\LW5dUSU6JRWK=
CCRF-CEM	M1XWN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWfJR\|UxRTBwMEK1OFMh\|ryP	MXfTRW5ITVJ?
HUTU-80	NIjifIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mlf0TWM2OD1yLkCyOlI1KM7:TR?=	MWTTRW5ITVJ?
NCI-H1648	MlXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWrUWFhuUUN3ME2wMlAzPjR5IN88US=>	MmLKV2FPT0WU
HCE-4	NUnXZ5h[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2O5TGlEPTB;MD6wNlY5OiEQvF2=	M1jtOXNCVkeHUh?=
ETK-1	NETqd\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3TVT2lEPTB;MD6wNlc{PiEQvF2=	MYPTRW5ITVJ?
TE-15	MmqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3mxWmlEPTB;MD6wNlc{QCEQvF2=	MlzRV2FPT0WU
BE-13	M4rrOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWLaVWtvUUN3ME2wMlAzPzRizszN	NGPIOWpUSU6JRWK=
KE-37	NUOwNIZvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1nEZWlEPTB;MD6wNlc1OSEQvF2=	MmPiV2FPT0WU
NCI-H1355	M4f5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlfNTWM2OD1yLkCyO\|g{KM7:TR?=	NFnIe2dUSU6JRWK=
TE-11	MlrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkXoTWM2OD1yLkCyPFA6KM7:TR?=	Moj0V2FPT0WU
BL-70	MkHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MorxTWM2OD1yLkCyPFU4KM7:TR?=	NFTlW25USU6JRWK=
ES6	Mor5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn[4TWM2OD1yLkCyPFgyKM7:TR?=	NGjCbWlUSU6JRWK=
GT3TKB	NHjMbXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGO4VXNKSzVyPUCuNFI6PTNizszN	NHztWY5USU6JRWK=
LB647-SCLC	NFfmW3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYLDToFKUUN3ME2wMlA{OTl3IN88US=>	NFzMepJUSU6JRWK=
NB13	NXXxd3ExT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mo\FTWM2OD1yLkCzN\|E3KM7:TR?=	NYm2Ro1lW0GQR1XS
ST486	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MofSTWM2OD1yLkCzN\|M4KM7:TR?=	NV;SSJdqW0GQR1XS
NCI-H82	M4PLWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTBwMEOzOFMh\|ryP	MWnTRW5ITVJ?
NTERA-S-cl-D1	Mm\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFKw[I9KSzVyPUCuNFM{QTlizszN	NFO3NVZUSU6JRWK=
ES4	NVTUTGpXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUHQU2xuUUN3ME2wMlA{PDZ\|IN88US=>	NXTMT29zW0GQR1XS
SK-NEP-1	NVPBOHRCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIG2W3dKSzVyPUCuNFM1QTlizszN	MYjTRW5ITVJ?
Becker	NHrFTW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYe1SI9SUUN3ME2wMlA{PTV3IN88US=>	NVjyT5U4W0GQR1XS
A101D	NVvTPZZWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFnQUGRKSzVyPUCuNFM4PDhizszN	MXfTRW5ITVJ?
SK-UT-1	Mn72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3\5cWlEPTB;MD6wN\|c4PCEQvF2=	NGLKR5dUSU6JRWK=
SW982	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1nhW2lEPTB;MD6wN\|c6KM7:TR?=	MXzTRW5ITVJ?
TE-10	NIfifHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M17q[GlEPTB;MD6wOFA1PiEQvF2=	M37VNnNCVkeHUh?=
OVCAR-4	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV3UfFBjUUN3ME2wMlA1ODV7IN88US=>	M{[5U3NCVkeHUh?=
KP-N-YS	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmfFTWM2OD1yLkC0NFg2KM7:TR?=	NHPEOIFUSU6JRWK=
BL-41	M4HsUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MY\JR\|UxRTBwMESxNlUh\|ryP	MnjFV2FPT0WU
MZ1-PC	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF3jRWJKSzVyPUCuNFQyOjdizszN	MlG3V2FPT0WU
PF-382	NEHhfm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{HkdWlEPTB;MD6wOFE6QCEQvF2=	NHfq[JBUSU6JRWK=
MOLT-13	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXz6NFgzUUN3ME2wMlA1OjN6IN88US=>	NFnqRnlUSU6JRWK=
HCC1599	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4Oy[WlEPTB;MD6wOFI2QCEQvF2=	NVjJUIlTW0GQR1XS
IST-MEL1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTBwMES0OFIh\|ryP	NVPrNoIxW0GQR1XS
LU-139	M3PkPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXHJR\|UxRTBwMES0OFIh\|ryP	NH[wfY9USU6JRWK=
MS-1	NXzHPVlET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIToPJRKSzVyPUCuNFQ4ODFizszN	M1zHXHNCVkeHUh?=
MFH-ino	NYjsNpVPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUj4eHRSUUN3ME2wMlA2ODB\|IN88US=>	M1y2[XNCVkeHUh?=
IMR-5	NWf1eHdxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXrQUW86UUN3ME2wMlA2ODJzIN88US=>	MkHZV2FPT0WU
TE-5	MlrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkjWTWM2OD1yLkC1NFY{KM7:TR?=	MljtV2FPT0WU
DJM-1	NUjSNm91T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4XhbmlEPTB;MD6wOVE1OiEQvF2=	M1\vfnNCVkeHUh?=
NB17	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MljKTWM2OD1yLkC1NlA4KM7:TR?=	MXfTRW5ITVJ?
KARPAS-45	NWXqb3o5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTBwMEWzOVgh\|ryP	NYrmdnhjW0GQR1XS
TGBC1TKB	MnrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWThbW0yUUN3ME2wMlA2PDB3IN88US=>	M1ztXnNCVkeHUh?=
ML-2	NIexZWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGjjeXdKSzVyPUCuNFU1OTRizszN	NYLXfZhvW0GQR1XS
no-10	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkfWTWM2OD1yLkC1OFc1KM7:TR?=	Mn7vV2FPT0WU
CTV-1	NHG5TpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml;xTWM2OD1yLkC1OVAzKM7:TR?=	M4jmfHNCVkeHUh?=
SJSA-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFHxWpBKSzVyPUCuNFU2OiEQvF2=	Mmq1V2FPT0WU
HC-1	MoDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYDJR\|UxRTBwMEW1PVch\|ryP	M3LiUHNCVkeHUh?=
TE-12	M4HlTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlX5TWM2OD1yLkC1OlE{KM7:TR?=	NXnYeIxoW0GQR1XS
KY821	M3jP[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV;JfZZFUUN3ME2wMlA2PjN{IN88US=>	NYH1[5duW0GQR1XS
TALL-1	NYrMcFNST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIO3R4ZKSzVyPUCuNFU4ODhizszN	NXHnN4NwW0GQR1XS
DEL	NGjBTmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGKyXXVKSzVyPUCuNFU4ODlizszN	NIDv[WhUSU6JRWK=
TE-6	NH;NV\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWTJR\|UxRTBwMEW3NlIh\|ryP	NHz3U4FUSU6JRWK=
SK-LMS-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWP3OmhTUUN3ME2wMlA2QDB3IN88US=>	M3XRUXNCVkeHUh?=
EW-1	NVX5UoFPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn\qTWM2OD1yLkC1PFM4KM7:TR?=	NUfWU5dsW0GQR1XS
8-MG-BA	NF7a[plIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1Lpe2lEPTB;MD6wOVg2OSEQvF2=	MWHTRW5ITVJ?
NALM-6	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnPoTWM2OD1yLkC1PVc{KM7:TR?=	MkjTV2FPT0WU
LB771-HNC	M125O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{HJfmlEPTB;MD6wOVk4QSEQvF2=	MoroV2FPT0WU
HT-144	NF[xd5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWWwO5dOUUN3ME2wMlA3OTNizszN	Mn;OV2FPT0WU
KM-H2	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoHPTWM2OD1yLkC2NlIyKM7:TR?=	NEX4OFdUSU6JRWK=
SF268	NVO1WotJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGnRfVRKSzVyPUCuNFYzQDZizszN	M13MVHNCVkeHUh?=
RS4-11	Mmq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHj1ZpFKSzVyPUCuNFY{ODRizszN	Mmm3V2FPT0WU
MHH-PREB-1	NX3kfldVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MknGTWM2OD1yLkC2N\|E6KM7:TR?=	NWTGU5htW0GQR1XS
ATN-1	M1T1dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkTuTWM2OD1yLkC2N\|Q2KM7:TR?=	NEXZfGFUSU6JRWK=
BB30-HNC	MoTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYHJR\|UxRTBwME[0N\|Yh\|ryP	NIL4bIdUSU6JRWK=
CPC-N	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHTpTFBKSzVyPUCuNFY2OjRizszN	M{S0UXNCVkeHUh?=
NB1	MonvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFrCN5pKSzVyPUCuNFY3OTNizszN	NFfDbXNUSU6JRWK=
KS-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWLJR\|UxRTBwME[3OFgh\|ryP	NGm0NnpUSU6JRWK=
RXF393	Mm\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnTMTWM2OD1yLkC2O\|Y1KM7:TR?=	M1P1SXNCVkeHUh?=
IST-SL2	NY\pNFB1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn;ZTWM2OD1yLkC3NFA1KM7:TR?=	MWjTRW5ITVJ?
GI-ME-N	M{XXS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2jvVGlEPTB;MD6wO\|I5PiEQvF2=	MYfTRW5ITVJ?
VA-ES-BJ	NWixd3ZWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1;STWlEPTB;MD6wO\|Q4PSEQvF2=	NWLJ[YJRW0GQR1XS
NCI-H1581	MkL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmLJTWM2OD1yLkC3OFc5KM7:TR?=	Mm\SV2FPT0WU
U-266	NGfpco9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlLPTWM2OD1yLkC3OFk4KM7:TR?=	MYLTRW5ITVJ?
DMS-114	NWPESJpuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2\WeWlEPTB;MD6wO\|UzQCEQvF2=	NXXTXFUyW0GQR1XS
NCI-H187	NG\zSVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn;3TWM2OD1yLkC3O\|I3KM7:TR?=	NYGyeWFzW0GQR1XS
SW962	NYK4cZp3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGjGR2JKSzVyPUCuNFc5OzlizszN	NVPyUHNTW0GQR1XS
MONO-MAC-6	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRTBwMEe5PFYh\|ryP	M3fHOHNCVkeHUh?=
MOLT-16	NX\FNGhNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mo\FTWM2OD1yLkC4NVIyKM7:TR?=	M{nmS3NCVkeHUh?=
KNS-42	NWjiV41tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4fqbGlEPTB;MD6wPFE3OSEQvF2=	NUHMTI9lW0GQR1XS
CMK	NHTiNmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{XRTmlEPTB;MD6wPFIzPSEQvF2=	MX7TRW5ITVJ?
Ramos-2G6-4C10	NUftdldCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVXJR\|UxRTBwMEiyNlUh\|ryP	NIXXV\|JUSU6JRWK=
Daudi	NWP3Tmx3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MljJTWM2OD1yLkC4NlU3KM7:TR?=	MnnDV2FPT0WU
NCI-H510A	M3PocWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTBwMEizN\|Yh\|ryP	NGjBXVBUSU6JRWK=
LB831-BLC	M3LRe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1XkVWlEPTB;MD6wPFU3OSEQvF2=	NGXQcHlUSU6JRWK=
HEL	MmTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIr6fJZKSzVyPUCuNFg3PjhizszN	NVroRo42W0GQR1XS
LU-134-A	M32zfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIO5enlKSzVyPUCuNFg4ODhizszN	MlXFV2FPT0WU
NCI-H1694	NHLB[HZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWXJR\|UxRTBwMEi3OFQh\|ryP	MUPTRW5ITVJ?
KGN	M3ryV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{DXOGlEPTB;MD6wPFc2QSEQvF2=	NIDCU3hUSU6JRWK=
A253	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{fvbmlEPTB;MD6wPFgzOiEQvF2=	M{jib3NCVkeHUh?=
DG-75	NVnIXoNrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVzuVHBxUUN3ME2wMlA5QTJ{IN88US=>	NGnPNW1USU6JRWK=
MOLT-4	MnzkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoLxTWM2OD1yLkC4PVg{KM7:TR?=	NXLmV48yW0GQR1XS
NCI-SNU-5	M2jrTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUPJR\|UxRTBwMEmyOVgh\|ryP	NWT4cpZ{W0GQR1XS
ONS-76	M{O2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1:0dGlEPTB;MD6wPVI4PiEQvF2=	M1rpfHNCVkeHUh?=
NCI-H446	Mo\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEX6SVJKSzVyPUCuNFk1PjJizszN	MUjTRW5ITVJ?
COR-L279	M33wcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NILlRmZKSzVyPUCuNFk2PTZizszN	MVjTRW5ITVJ?
Calu-6	NH\0OXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYXUUI9mUUN3ME2wMlA6PTl6IN88US=>	NXPxeHBUW0GQR1XS
BC-3	M17FNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVnJR\|UxRTBwMEm2OlIh\|ryP	MmnHV2FPT0WU
NCI-H2126	M13QNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRTBwMEm3PVEh\|ryP	MWTTRW5ITVJ?
NCI-H1882	M3P4OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml\oTWM2OD1yLkC5PFA6KM7:TR?=	Mnv6V2FPT0WU
BB65-RCC	M4fhXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV7uVnlpUUN3ME2wMlExOjl2IN88US=>	NYG1ZllQW0GQR1XS
DU-4475	MoOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXrJR\|UxRTBwMUC0NFch\|ryP	MXPTRW5ITVJ?
NCI-H526	NXrNfodoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF7XdGVKSzVyPUCuNVA1PCEQvF2=	Mn\NV2FPT0WU
NEC8	M{Ho[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NILaPIFKSzVyPUCuNVA2OjVizszN	NXnZWZNyW0GQR1XS
NCI-H1304	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF3TNmFKSzVyPUCuNVA2QTRizszN	MUHTRW5ITVJ?
L-540	M1jZVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml3ETWM2OD1yLkGwO\|A5KM7:TR?=	MYDTRW5ITVJ?
NCI-SNU-16	NYr3fGx[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NE[2cI1KSzVyPUCuNVA4PDJizszN	NYrFc216W0GQR1XS
HD-MY-Z	NVy4NoFJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRTBwMUC4OVYh\|ryP	NVvVWnE2W0GQR1XS
K-562	NEnseXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIrMfVNKSzVyPUCuNVA5PThizszN	Mkm0V2FPT0WU
JAR	NW\5SHpYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2HEN2lEPTB;MD6xNFkzPSEQvF2=	NXXqdnFOW0GQR1XS
MZ2-MEL	NFTwT2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWLJR\|UxRTBwMUGwOUDPxE1?	NYnmT4VUW0GQR1XS
L-363	NGP2OoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2eyN2lEPTB;MD6xNVA4QSEQvF2=	M{HZOnNCVkeHUh?=
BV-173	NWTUfJBPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHnUTGFKSzVyPUCuNVEzPDNizszN	NXXuTVFkW0GQR1XS
NCI-H524	NWnSWINkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGOyPW5KSzVyPUCuNVEzPzRizszN	NILNRohUSU6JRWK=
EoL-1-cell	MorlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3rHOWlEPTB;MD6xNVY4OiEQvF2=	MWrTRW5ITVJ?
K052	NILJRYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3\zNGlEPTB;MD6xNVcyOiEQvF2=	M1;wZXNCVkeHUh?=
TK10	NVzTW4FTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWe1NY1XUUN3ME2wMlEyPzJ6IN88US=>	M37ud3NCVkeHUh?=
KU812	MlT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGqyU5NKSzVyPUCuNVIxPDRizszN	M1T2cnNCVkeHUh?=
RPMI-8226	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MofGTWM2OD1yLkGyNFUzKM7:TR?=	NF3tRWFUSU6JRWK=
MZ7-mel	NGraXVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmnLTWM2OD1yLkGyNlM4KM7:TR?=	NYq5VGlWW0GQR1XS
SK-PN-DW	M{\pR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mom5TWM2OD1yLkGyNlg4KM7:TR?=	NXLjS4dHW0GQR1XS
SR	NXHDb5FtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIHZR5VKSzVyPUCuNVI1PDFizszN	M37zN3NCVkeHUh?=
RPMI-6666	NYLENoFpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2H6SGlEPTB;MD6xNlc1OyEQvF2=	NV3z[JFDW0GQR1XS
no-11	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRTBwMUK4Olkh\|ryP	NX3jVodHW0GQR1XS
EW-3	MnTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGDQNHRKSzVyPUCuNVI5QTNizszN	MWDTRW5ITVJ?
LAMA-84	NGXle2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3fMZ2lEPTB;MD6xN\|E5PyEQvF2=	M1vRWnNCVkeHUh?=
HT	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXnJR\|UxRTBwMUO1O\|Qh\|ryP	NEjDdFZUSU6JRWK=
KP-N-RT-BM-1	NHnHV2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlvVTWM2OD1yLkGzOlEzKM7:TR?=	MkfzV2FPT0WU
NCI-H747	M{DheGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoHPTWM2OD1yLkGzO{DPxE1?	M1rRfXNCVkeHUh?=
NCCIT	MliwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NISxdpdKSzVyPUCuNVM6OzlizszN	NUP5NlVFW0GQR1XS
MLMA	MnXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{jHOmlEPTB;MD6xOFE3PyEQvF2=	Mo\iV2FPT0WU
LP-1	MknsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MonETWM2OD1yLkG0NlQh\|ryP	NEHKVmNUSU6JRWK=
CAL-148	NIP5SFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1rZ[GlEPTB;MD6xOFQ5OyEQvF2=	MmO5V2FPT0WU
GB-1	NIjKcYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIf4PFJKSzVyPUCuNVQ2OjZizszN	MV3TRW5ITVJ?
COR-L88	MkDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn3GTWM2OD1yLkG0PFAzKM7:TR?=	NYHMbnI{W0GQR1XS
NKM-1	M4fUR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NG\LR5pKSzVyPUCuNVQ6ODZizszN	MVrTRW5ITVJ?
NB5	NInDN\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmToTWM2OD1yLkG1OFYzKM7:TR?=	M3rP[3NCVkeHUh?=
SH-4	M3r5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUjUcHFNUUN3ME2wMlE2PDZ4IN88US=>	NYrtWZpyW0GQR1XS
EM-2	Mo\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHXZUo5KSzVyPUCuNVU1PjdizszN	Mnr6V2FPT0WU
TGBC24TKB	NFrzN25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGnrRVJKSzVyPUCuNVU3PTlizszN	NHXmPJNUSU6JRWK=
SCLC-21H	MkjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXLJR\|UxRTBwMUW3NFIh\|ryP	NVLRW41ZW0GQR1XS
COLO-684	NXH4XYdPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkPVTWM2OD1yLkG1O\|IyKM7:TR?=	M33SWnNCVkeHUh?=
KINGS-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlTiTWM2OD1yLkG1PVEh\|ryP	M2jjRnNCVkeHUh?=
LS-123	NHmwTXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4XVRmlEPTB;MD6xOVkyPyEQvF2=	NFO2bFZUSU6JRWK=
MC116	NU\vTGNzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHO0UZVKSzVyPUCuNVYyPThizszN	NHz2OIZUSU6JRWK=
SU-DHL-1	MnzJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXPrOYl6UUN3ME2wMlE3OjB4IN88US=>	NXzRUlJ1W0GQR1XS
NCI-H64	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTBwMU[zOFch\|ryP	M4TGfnNCVkeHUh?=
HCE-T	NIrVcIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXXJR\|UxRTBwMU[1NFQh\|ryP	NFXocG5USU6JRWK=
LOXIMVI	NHXLbIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3HEXmlEPTB;MD6xOlk1QSEQvF2=	Ml30V2FPT0WU
ARH-77	MnzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NInaO\|JKSzVyPUCuNVc{PzlizszN	MorzV2FPT0WU
DOHH-2	Mn\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVLBd5FrUUN3ME2wMlE4Pjd{IN88US=>	M{LBNXNCVkeHUh?=
COLO-320-HSR	NYfnRo53T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUPJR\|UxRTBwMUixOVQh\|ryP	M{TDfXNCVkeHUh?=
NB6	NVfzNFVUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mo[zTWM2OD1yLkG4OVY3KM7:TR?=	M4rWVXNCVkeHUh?=
L-428	M3\C[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXPNVVhtUUN3ME2wMlE5QDF\|IN88US=>	Mo\1V2FPT0WU
SNB75	MoPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTBwMUi4NlQh\|ryP	M{DUb3NCVkeHUh?=
NCI-H2141	NYWzdpcxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MknFTWM2OD1yLkG5NFEyKM7:TR?=	NYnEN3hEW0GQR1XS
KARPAS-299	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIL4cFlKSzVyPUCuNVkzPDFizszN	M3XibHNCVkeHUh?=
LC4-1	Ml7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1HucGlEPTB;MD6xPVUxOiEQvF2=	MnrEV2FPT0WU
UACC-257	NF7RNZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTBwMUm5OFch\|ryP	MlvTV2FPT0WU
EVSA-T	M2PPd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmrwTWM2OD1yLkKwN\|EzKM7:TR?=	MmPIV2FPT0WU
JiyoyeP-2003	Moe2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml7PTWM2OD1yLkKwOFc4KM7:TR?=	MoDjV2FPT0WU
NCI-H720	M4\4Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn30TWM2OD1yLkKwOVI2KM7:TR?=	MlGwV2FPT0WU
GAK	M1jDTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnixTWM2OD1yLkKxNVg6KM7:TR?=	MkDzV2FPT0WU
HH	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{i4W2lEPTB;MD6yNVQxPSEQvF2=	NGfZUJlUSU6JRWK=
NCI-H1436	Ml\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1\4VWlEPTB;MD6yNVQ3PCEQvF2=	NX;XeHlsW0GQR1XS
GR-ST	M4nJb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXvJR\|UxRTBwMkG0PFgh\|ryP	M{T4RnNCVkeHUh?=
BC-1	NWHtW4xJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M33ZfGlEPTB;MD6yNlYyPiEQvF2=	NXrLOldjW0GQR1XS
SIG-M5	NGLXNoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkfXTWM2OD1yLkKyO\|I4KM7:TR?=	Mo\uV2FPT0WU
NCI-H345	MojzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHqxSGFKSzVyPUCuNlM5ODVizszN	NWeyPYVzW0GQR1XS
OPM-2	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHOwcI1KSzVyPUCuNlM5QDJizszN	NWLkbHV2W0GQR1XS
LB1047-RCC	M3nQTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHHNVpNKSzVyPUCuNlQ1OSEQvF2=	MV\TRW5ITVJ?
CTB-1	M2nCd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUDJR\|UxRTBwMkS0PVMh\|ryP	MVrTRW5ITVJ?
A3-KAW	MmHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGjuR2lKSzVyPUCuNlU{PDFizszN	MYHTRW5ITVJ?
SF126	NEf2ZWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTBwMkWzPFMh\|ryP	MX;TRW5ITVJ?
KARPAS-422	NF31WYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTBwMkW0N\|Uh\|ryP	MkPoV2FPT0WU
MEG-01	NGnkWWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV7mTmZQUUN3ME2wMlI2Pjd\|IN88US=>	Mn3pV2FPT0WU
NCI-H209	M1LueWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYTBU48yUUN3ME2wMlI3Ozd2IN88US=>	NH;vOGFUSU6JRWK=
SBC-1	Mm\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUXuT\|dXUUN3ME2wMlI3PSEQvF2=	NWHEe29rW0GQR1XS
K5	NHPOWnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NELLZmJKSzVyPUCuNlY6QDRizszN	NVPjdodVW0GQR1XS
QIMR-WIL	NVnqO5FST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1HsRWlEPTB;MD6yO\|E2PSEQvF2=	NILKfZhUSU6JRWK=
NMC-G1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{TFW2lEPTB;MD6yPFIyPyEQvF2=	M2DYeHNCVkeHUh?=
IST-MES1	NEe3PZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnL4TWM2OD1yLkK5NlM5KM7:TR?=	NXfifFNNW0GQR1XS
SW684	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHH0fVhKSzVyPUCuN\|AxPDdizszN	NWfzT2RkW0GQR1XS
MV-4-11	NF;JNWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTBwM{C3PFgh\|ryP	MUHTRW5ITVJ?
LAN-6	NVLLV\|BrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV\JR\|UxRTBwM{G1O\|Ih\|ryP	MkK5V2FPT0WU
RH-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3jv[GlEPTB;MD6zNVg4OSEQvF2=	NWTH[WR1W0GQR1XS
CP66-MEL	NHS2bGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{XPO2lEPTB;MD6zNVg4QCEQvF2=	MVzTRW5ITVJ?
EC-GI-10	NWDrSoRmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXXJR\|UxRTBwM{K5PFch\|ryP	NVTpNYduW0GQR1XS
GDM-1	Ml7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTBwM{OwOVkh\|ryP	MWfTRW5ITVJ?
IST-SL1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkLaTWM2OD1yLkO0PVE1KM7:TR?=	M2\GT3NCVkeHUh?=
KMOE-2	MkPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVq4N2ZbUUN3ME2wMlM2OTd3IN88US=>	NFT0S4FUSU6JRWK=
OS-RC-2	NFLL[JpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHToW3hKSzVyPUCuN\|U2PDRizszN	NF3EXXNUSU6JRWK=
HDLM-2	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF2xeHJKSzVyPUCuN\|c5OTRizszN	MYHTRW5ITVJ?
DSH1	Mn7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGDadGFKSzVyPUCuN\|g3OzFizszN	NYn6SpdVW0GQR1XS
LS-1034	Mn\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4HCfmlEPTB;MD6zPFk2PCEQvF2=	MUTTRW5ITVJ?
LB373-MEL-D	MmPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\uTGlEPTB;MD6zPVE6PyEQvF2=	MYXTRW5ITVJ?
GOTO	NETPc4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmPFTWM2OD1yLkSyNVE5KM7:TR?=	NWX5OIZPW0GQR1XS
MRK-nu-1	M2HVT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2C2c2lEPTB;MD60NlIxPSEQvF2=	NGrseG1USU6JRWK=
SK-MM-2	M124XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX7Dd4RYUUN3ME2wMlQ{PDR{IN88US=>	MUfTRW5ITVJ?
BOKU	NYPtT4FYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFfa[G9KSzVyPUCuOFM4QTJizszN	NHrr[\|BUSU6JRWK=
NOMO-1	Mn3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3HCc2lEPTB;MD60N\|g3KM7:TR?=	MlK2V2FPT0WU
J-RT3-T3-5	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVTJR\|UxRTBwNES4O\|gh\|ryP	MnvEV2FPT0WU
COLO-668	MnXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWfJR\|UxRTBwNEW2Olgh\|ryP	MX;TRW5ITVJ?
SF539	M{LtXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTBwNEi2PFQh\|ryP	NIi5TXFUSU6JRWK=
LB2518-MEL	M4XzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFjVS4dKSzVyPUCuOFk4ODNizszN	M37F[3NCVkeHUh?=
TE-441-T	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTBwNUCxNkDPxE1?	MonKV2FPT0WU
MDA-MB-134-VI	MmfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mnq3TWM2OD1yLkWwPVIyKM7:TR?=	MkH2V2FPT0WU
SCC-3	M2jIPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3LFXWlEPTB;MD61NVg4OyEQvF2=	MVjTRW5ITVJ?
KLE	NG\mbZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFTFNmNKSzVyPUCuOVIyPzFizszN	NUHPPZFYW0GQR1XS
LB2241-RCC	NIHRV\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWG0d\|l5UUN3ME2wMlUzPTJ3IN88US=>	MVfTRW5ITVJ?
NCI-H1417	NIPZTXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTBwNUO0N\|Uh\|ryP	M4jJV3NCVkeHUh?=
NCI-H2081	NFHyfIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTBwNUi2NVEh\|ryP	M2DVZXNCVkeHUh?=
NCI-H1522	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUHJR\|UxRTBwNUmzPFMh\|ryP	NXrKbnREW0GQR1XS
NCI-H889	NGLHfVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmHjTWM2OD1yLkW5PFQ1KM7:TR?=	NXziSolUW0GQR1XS
CGTH-W-1	M4TXb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NULoU5dCUUN3ME2wMlYxPzV3IN88US=>	NILrepdUSU6JRWK=
EB-3	NI\YXYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXnJR\|UxRTBwNkGxOVMh\|ryP	NW\xN\|c3W0GQR1XS
D-336MG	M2m2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmezTWM2OD1yLk[xO\|kyKM7:TR?=	M4eySHNCVkeHUh?=
LC-1F	Ml\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MY\JR\|UxRTBwNkK1PVIh\|ryP	Mn3QV2FPT0WU
MHH-NB-11	NIOweHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWezXWFLUUN3ME2wMlY{QDBzIN88US=>	MYPTRW5ITVJ?
SK-N-FI	NWTsV2p{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXTJR\|UxRTBwNkO5NUDPxE1?	MULTRW5ITVJ?
NCI-H69	NYfjXJZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVS3fmU4UUN3ME2wMlY1QDd7IN88US=>	NETKS4VUSU6JRWK=
SCH	NF2xNpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVroXIFrUUN3ME2wMlY3ODJ\|IN88US=>	M{TifnNCVkeHUh?=
LS-513	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3XGbmlEPTB;MD62O\|I2QSEQvF2=	NV\vO\|dKW0GQR1XS
CP67-MEL	NEPNcFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3rSd2lEPTB;MD62O\|U6PiEQvF2=	M4C0V3NCVkeHUh?=
GCIY	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV;JR\|UxRTBwN{CzOlMh\|ryP	NH3ad\|BUSU6JRWK=
SHP-77	M3SyNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHPmNGRKSzVyPUCuO\|A4OzRizszN	NXf6Olc6W0GQR1XS
EHEB	NIjmSoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUnVRXRuUUN3ME2wMlcyQDV2IN88US=>	MkfyV2FPT0WU
D-247MG	NGnWR25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2\tTmlEPTB;MD63N\|I{OiEQvF2=	M3zWOHNCVkeHUh?=
Raji	NX3KcY1tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVK5XYVqUUN3ME2wMlc1QTh7IN88US=>	MWDTRW5ITVJ?
MPP-89	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFjXdY9KSzVyPUCuO\|U6PzhizszN	MUfTRW5ITVJ?
EKVX	NWPDUIhKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NG\0V4hKSzVyPUCuO\|kxPzNizszN	NY\udoxGW0GQR1XS
HCC2218	NXzyU3F3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIn4fopKSzVyPUCuO\|kyOzFizszN	M4riUnNCVkeHUh?=
KNS-81-FD	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoXlTWM2OD1yLkixNFEyKM7:TR?=	NXn6ZmVJW0GQR1XS
HCC2157	NH\MV2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4XxeGlEPTB;MD64OFk2OSEQvF2=	M13ScHNCVkeHUh?=
BT-474	Mn;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUTo[od1UUN3ME2wMlg5QDV2IN88US=>	MornV2FPT0WU
NCI-H748	M2rFTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHXUbWlKSzVyPUCuPVEzKM7:TR?=	MUXTRW5ITVJ?
EW-24	M37BNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXPiXI53UUN3ME2wMlkzODB{IN88US=>	NWPJW3dJW0GQR1XS
D-263MG	MkfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH21RZpKSzVyPUCuPVQ2OTJizszN	NFO4O\|hUSU6JRWK=
OMC-1	Ml74S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkXXTWM2OD1yLkm2N\|c{KM7:TR?=	NGrQNZZUSU6JRWK=
NCI-H2196	NInaNHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2jpU2lEPTB;MD65O\|c4PyEQvF2=	NWDOe3BRW0GQR1XS
HAL-01	M2XYeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXvJR\|UxRTBwOUm4O\|Ih\|ryP	NETJSXNUSU6JRWK=
NCI-H2107	MlPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{PwV2lEPTB;MT6wNVg2PCEQvF2=	NV3ndYpRW0GQR1XS
LB996-RCC	MnHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFPwZ3hKSzVyPUGuNFgxPTFizszN	MWPTRW5ITVJ?
NCI-H1395	M1\ucGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkPCTWM2OD1zLkGwOlch\|ryP	MoT0V2FPT0WU
CHP-126	NEP2emhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MonpTWM2OD1zLkG2NVk6KM7:TR?=	NY\1Z\|U6W0GQR1XS
NB69	NYG1Top4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGnYR\|RKSzVyPUGuNlYyPDhizszN	M2DDc3NCVkeHUh?=
CAS-1	NFnFb\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmDETWM2OD1zLkO0NlMyKM7:TR?=	MUTTRW5ITVJ?
JVM-3	NGrXb41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3XsSmlEPTB;MT60O\|g2PSEQvF2=	NFS5OIxUSU6JRWK=
DMS-153	MnP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mnr4TWM2OD1zLkW3Olc1KM7:TR?=	NWnuXGxJW0GQR1XS
SK-MEL-2	NYq5VWh3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGPrToNKSzVyPUGuO\|E4QDlizszN	NXOxU484W0GQR1XS
NCI-H1155	NVq1W3pRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTFwN{O2O\|Yh\|ryP	NWrwWoUyW0GQR1XS
NCI-H1092	NYfEUJFlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGDpfINKSzVyPUGuO\|YyQDJizszN	MVfTRW5ITVJ?
LU-165	NIi5WHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIK5dWZKSzVyPUGuPFY1PzZizszN	Mo\DV2FPT0WU
HL-60	NV2yUpZWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkPMTWM2OD1zLkm5PVA5KM7:TR?=	NYDZW\|FxW0GQR1XS
REH	M37mN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF3EcG9KSzVyPUKuNFA2QDJizszN	M4HNSnNCVkeHUh?=
JVM-2	NXHWUY1FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH7IXFdKSzVyPUKuNFYyOzVizszN	MlL2V2FPT0WU
MN-60	MnvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnPQTWM2OD1{LkG3N\|A5KM7:TR?=	NF;HTVlUSU6JRWK=
SCC-15	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkKzTWM2OD1{LkKwNlch\|ryP	M{TGXXNCVkeHUh?=
SNU-C1	NGrnc2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4jx[GlEPTB;Mj6yNVM1OyEQvF2=	MlTDV2FPT0WU
SK-MEL-1	NVriV5E4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2ruOGlEPTB;Mj6zNlA1PyEQvF2=	MlzOV2FPT0WU
TGW	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYLJR\|UxRTJwM{WwNlch\|ryP	M2XZWnNCVkeHUh?=
CA46	NFvDWVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUXJR\|UxRTJwN{W5Olch\|ryP	MljjV2FPT0WU
NCI-H23	NVi0eGdOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTJwOEC3PVEh\|ryP	MoDIV2FPT0WU
MMAC-SF	NHnISpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXrJR\|UxRTJwOE[2Nlgh\|ryP	MUDTRW5ITVJ?
NCI-H2171	M1i5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mk\nTWM2OD1\|LkCzOFQ5KM7:TR?=	NGDaWFRUSU6JRWK=
A704	NGr3bYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEPvNmpKSzVyPUOuNVQyQTRizszN	MoHWV2FPT0WU
DB	NV3SbGtNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjJR\|UxRTNwMkW1O\|Yh\|ryP	MXLTRW5ITVJ?
NCI-H719	NYLOZWRKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV;WPFdJUUN3ME2zMlMxOzh2IN88US=>	NVPZNIJ1W0GQR1XS
MC-CAR	MlTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1zGN2lEPTB;Mz61OFgyPyEQvF2=	NUDhNoQ6W0GQR1XS
SIMA	NFrsTpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWqyRW8yUUN3ME2zMlU5PDF4IN88US=>	NH;aW\|NUSU6JRWK=
SW872	MmG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV;JR\|UxRTNwN{ixNFEh\|ryP	NWLNd3g1W0GQR1XS
HCC1187	M3XhWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTNwN{izNVUh\|ryP	M1uwZ3NCVkeHUh?=
EW-13	MlfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFXvbVFKSzVyPUOuPFM1OTdizszN	M3njS3NCVkeHUh?=
NCI-SNU-1	M1u2bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2XZXWlEPTB;ND6yNVk6QSEQvF2=	MX7TRW5ITVJ?
NCI-H226	NXj1dIpyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYGweYpVUUN3ME20MlM{PjB4IN88US=>	MkXmV2FPT0WU
RPMI-8866	M1zZZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWDJR\|UxRTRwM{[wNlkh\|ryP	NVzuWG1JW0GQR1XS
OCI-AML2	NX3R[5BJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV;CUGdJUUN3ME20MlU2OjNizszN	NY\3Zos3W0GQR1XS
LU-65	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYf2T402UUN3ME20Mlk{ODN\|IN88US=>	M1L0OXNCVkeHUh?=
SK-N-DZ	M{Hvb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVW2c2RbUUN3ME21MlY{PDZ3IN88US=>	MoDYV2FPT0WU
NB14	MmrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIjuSFdKSzVyPUWuPVcyOzVizszN	M{TQZXNCVkeHUh?=
COLO-829	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoL0TWM2OD14LkOzN\|U6KM7:TR?=	NGHCdWhUSU6JRWK=
MHH-CALL-2	M2PNdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRTZwNUG1NFgh\|ryP	MmrjV2FPT0WU
NCI-H1770	NFPv[mpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MY\JR\|UxRTZwNk[5NFQh\|ryP	NITYSppUSU6JRWK=
ECC4	NVO1ZphRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4DadWlEPTB;Nj64NlE4QSEQvF2=	MVjTRW5ITVJ?
A498	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2e2fmlEPTB;Nj64O\|E6OiEQvF2=	MYnTRW5ITVJ?
DMS-79	NV\BXpdxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUDJR\|UxRTdwMES1NVIh\|ryP	NIKyZWVUSU6JRWK=
P30-OHK	NXy2Z5A3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHfvZ4pKSzVyPUeuNlE6ODZizszN	NVvnUYhRW0GQR1XS
D-502MG	M1;3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHnDV5hKSzVyPUeuPVg{PiEQvF2=	NX;weJl5W0GQR1XS
RCC10RGB	NFHNcoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXfPUlRRUUN3ME24MlA3OjhizszN	MlXwV2FPT0WU
U-698-M	M3;oUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYTLW2x2UUN3ME24MlI6OjJ4IN88US=>	NYW4VHdMW0GQR1XS
BB49-HNC	NITFbJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWXJR\|UxRTlwNEKyOlUh\|ryP	M37PSnNCVkeHUh?=
ES1	NEPNOJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTlwNki5OVYh\|ryP	MojqV2FPT0WU
MFM-223	NIDVTGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTFyLkm5Nlch\|ryP	NETBO29USU6JRWK=
C2BBe1	M3Pybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1XncmlEPTB;MUGuN\|UzOyEQvF2=	NGTTPVdUSU6JRWK=
EB2	NFf6T2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYLJR\|UxRTF{Lk[4PFEh\|ryP	NYf4UnNVW0GQR1XS
C8166	M{K2[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYnZNG1UUUN3ME2xN{45OzB\|IN88US=>	NG\6OoNUSU6JRWK=
ES3	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnLGTWM2OD1zMz65PVc4KM7:TR?=	NWLGb5RmW0GQR1XS
NCI-H1650	MmfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{jDRmlEPTB;MU[uN\|c3PSEQvF2=	M2nxenNCVkeHUh?=
Mo-T	NEnleGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\JTWM2OD1zNz60NFI6KM7:TR?=	NV3pSZNxW0GQR1XS
NB7	M1PncGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVrKPZllUUN3ME2xO{44PDZ5IN88US=>	Mmj3V2FPT0WU
ES7	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MljsTWM2OD1zOT61OVA4KM7:TR?=	M33aNHNCVkeHUh?=
ES5	NFHkT2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MljyTWM2OD1{MT63OlcyKM7:TR?=	M4DJbXNCVkeHUh?=
MSTO-211H	MoDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NG\GSHdKSzVyPUKxMlg5PThizszN	M3e4RnNCVkeHUh?=
U-87-MG	NXy3d4NNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEi3T\|ZKSzVyPUK1MlE6PjZizszN	MUXTRW5ITVJ?
THP-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NY[yZlVwUUN3ME2yPU44OjBzIN88US=>	MkTUV2FPT0WU
NB10	M1Xqc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MY\JR\|UxRTNyLkK2PVQh\|ryP	MoDRV2FPT0WU
NH-12	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIfENYZKSzVyPUOzMlIxOTdizszN	MYPTRW5ITVJ?
COLO-824	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NELDXHJKSzVyPUO0MlExODZizszN	MYDTRW5ITVJ?
SKM-1	NXzSc\|loT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGn2eY5KSzVyPUO3Mlg1OjJizszN	MlXxV2FPT0WU
NCI-H1838	NHvBWplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIjnZ2pKSzVyPUO4MlM4QTdizszN	MWPTRW5ITVJ?
RL	NWf0OZQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXzXV5g5UUN3ME2zPU4zPDd5IN88US=>	MlnkV2FPT0WU
COLO-800	MnewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV3QR41SUUN3ME20NE4xPzd\|IN88US=>	NVXCN\|I5W0GQR1XS
KG-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3zRSGlEPTB;NECuPFk2PSEQvF2=	MV;TRW5ITVJ?
TUR	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mkj5TWM2OD12MT62N\|k6KM7:TR?=	NULBPWRQW0GQR1XS
LNCaP-Clone-FGC	NVvod2ZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml3rTWM2OD12MT65NFE4KM7:TR?=	NXy4NFBjW0GQR1XS
NCI-H322M	NUHwb\|JtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M17wdGlEPTB;NEKuOVk5PCEQvF2=	MX;TRW5ITVJ?
LNCaP	NWLMSmxoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFvrW2NKSzVyPUmxMlMhdk1?	MYGyOVUxPTF5NB?=
C4-2	NIS3XXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYLJR\|UxRThibl2=	MUOyOVUxPTF5NB?=
JURKAT	MkW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGLs[4YzPCCq		MV\JR\|UxRTRzNj62OkBvVQ>?	MlvWNlQ2OTl7OUW=
MOLT-4	M3ezb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mnm1NlQhcA>?		NHzONllKSzVyPUK4OVMvPSCwTR?=	MmC4NlQ2OTl7OUW=
REH	MkDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3TKWVI1KGh?		NV;BSWFwUUN3ME2yPFcvPjhibl2=	Mlj0NlQ2OTl7OUW=
NALM-6	NVe2cFVQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3K2eVI1KGh?		NGXu[HVKSzVyPUO0N\|MxKG6P	NXTtS4M5OjR3MUm5PVU>
RS 4;11	NV\1NVhjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFjxeVIzPCCq		MXLJR\|UxRTVzOT6wOUBvVQ>?	NXPkbodOOjR3MUm5PVU>
697	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGjIcGYzPCCq		MXrJR\|UxRTJzMEeuNUBvVQ>?	MVSyOFUyQTl7NR?=
SIL-ALL	NHzBS5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NH75N5EzPCCq		NHnXfWlKSzVyPUG5PU44PyCwTR?=	MnjVNlQ2OTl7OUW=
CEM	NVS5c3lIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXWyOEBp		M4DkSGlEPTB;NUKuNVghdk1?	MXOyOFUyQTl7NR?=
P12	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{jmNVI1KGh?		M3v5WGlEPTB;M{muNlchdk1?	MXeyOFUyQTl7NR?=
NALM-16	MkmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NUHLTYh5OjRiaB?=		M{DtfmlEPTB;OU[uNlghdk1?	MkLLNlQ2OTl7OUW=
JURKAT	NHLudXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYLWS5FqPDhiaB?=		Mn;GTWM2OD1zND64OEBvVQ>?	M2\PbVI1PTF7OUm1
MOLT-4	NV;ONoNST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MX60PEBp		NUe5VYR3UUN3ME2yOk43KG6P	NYD0XG12OjR3MUm5PVU>
REH	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{HpcFQ5KGh?		M3riTGlEPTB;NESuO\|Ehdk1?	NIizZ4YzPDVzOUm5OS=>
NALM-6	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVPVc2tyPDhiaB?=		NEm2bmlKSzVyPUKzMlI3KG6P	MomyNlQ2OTl7OUW=
RS 4;11	NYHlRYlZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWK0PEBp		MkjETWM2OD1zNkSuNlghdk1?	M2X6VFI1PTF7OUm1
697	MlXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVS0PEBp		M1n3UmlEPTB;M{C1MlMhdk1?	M3LyVVI1PTF7OUm1
SIL-ALL	M{jucWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnuwOFghcA>?		NVXTPYhEUUN3ME23OE43OiCwTR?=	NIHvdoozPDVzOUm5OS=>
CEM	M3qzXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2[zNlQ5KGh?		MYLJR\|UxRTJ2LkW1JI5O	NHfr[YgzPDVzOUm5OS=>
P12	NXjnN4pLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXHBVGQzPDhiaB?=		M2TmNWlEPTB;MUiuOFYhdk1?	MXSyOFUyQTl7NR?=
NALM-16	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXS0PEBp		NVnSUZVHUUN3ME22N{4zPCCwTR?=	NGHMVnAzPDVzOUm5OS=>
JURKAT	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NX\Z[pRWPzJiaB?=		M{jLcWlEPTB;Mz62OUBvVQ>?	M1nQSVI1PTF7OUm1
MOLT-4	NGrqdmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{TvOFczKGh?		M{\sUmlEPTB;Nz6zPUBvVQ>?	NGW2SIEzPDVzOUm5OS=>
REH	M2r3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUi3NkBp		M3nZXWlEPTB;MU[uNFEhdk1?	MljDNlQ2OTl7OUW=
NALM-6	NGSxOIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXK3NkBp		NITj[mJKSzVyPUGuO\|ghdk1?	MojnNlQ2OTl7OUW=
RS 4;11	Mkm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NEPZXo44OiCq		NEDOT\|JKSzVyPUSuN\|ghdk1?	NEn5UGYzPDVzOUm5OS=>
697	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MX[3NkBp		MVHJR\|UxRTd2LkK4JI5O	M1m3TlI1PTF7OUm1
SIL-ALL	NWfC[ZNMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYDKbpc5PzJiaB?=		NYXLc2VUUUN3ME23MlIhdk1?	MUGyOFUyQTl7NR?=
CEM	NH36ZmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1mxbVczKGh?		NEPsOZBKSzVyPUWuOFIhdk1?	NIH2d3MzPDVzOUm5OS=>
P12	NIq2UXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MV:3NkBp		NIDVcHBKSzVyPU[uN\|chdk1?	NXfNc5h3OjR3MUm5PVU>
NALM-16	M3nnOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MkLLO\|IhcA>?		MnfLTWM2OD15Nz63N{BvVQ>?	MlLpNlQ2OTl7OUW=
Y79	MkLmRZBweHSxc3nzJGF{e2G7	NFLTTmEyNTVyIH7N	NVTWeppMOTJxMkSgbC=>	M1;Y[GROW09?	NY[3SmpNcW6mdXPl[EBieG:ydH;zbZMhf2irY3igZ4FvKGKnIHXubIFv[2WmIHL5JGhV	MVOyOFM3PjZ4NR?=
WER-Rb-1	NWjWfGJzSXCxcITvd4l{KEG\|c3H5	NVzH[29ZOS13MDDuUS=>	NEOxcJcyOi9{NDDo	MofwSG1UVw>?	MlfobY5lfWOnZDDhdI9xfG:\|aYOge4hq[2hiY3HuJIJmKGWwaHHuZ4VlKGK7IFjU	MmTZNlQ{PjZ4NkW=
G7	M{fpWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRTNwMzDuUS=>	Mlj2NlQzODR5M{O=
G166	MmTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEfVeYxKSzVyPUeuNEBvVQ>?	MVOyOFIxPDd\|Mx?=
CB660	Mn;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1WwRWlEPTB;Nj60JI5O	MorWNlQzODR5M{O=
CB1117	NWjPVYFPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoLaTWM2OD1zNT62JI5O	MUWyOFIxPDd\|Mx?=
KB-3-1	NXzY[FJlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWTXOmtIUUN3ME2xMlQ5KMLzIECuOVMhdk1?	MWiyN\|k3OjR2NR?=
KB-8-5-11	NHPqeYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2PBOGlEPTB;NT6wNUDDuSB{LkCxJI5O	MUKyN\|k3OjR2NR?=
KB-C-1	NEnWV\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHTleY9KSzVyPUG2Mlc3KMLzIESuOVEhdk1?	NGPTSFUzOzl4MkS0OS=>
KB-V-1	Mk\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NG\uZ2VKSzVyPUK4NU4zPCEEsTCzNU42PyCwTR?=	M2fQTVI{QTZ{NES1
OVCAR-8	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{K3dmlEPTB;Nz6xPUDDuSB\|Lk[wJI5O	Mly3NlM6PjJ2NEW=
NCI-ADR-RES	MlHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFP2OmFKSzVyPUGyO\|MvOzBiwsGgNVkyNjJyIH7N	M3fQVlI{QTZ{NES1
MCF7	M4DBUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXzKdXd4UUN3ME21MlEyKMLzIEGuOFchdk1?	NHLSOXUzOzl4MkS0OS=>
MCF7-FLV1000	MlrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoXJTWM2OD1\|OUOuNVghyrFiN{SuPFMhdk1?	M1\tRVI{QTZ{NES1
S1	MnmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUPmXmVOUUN3ME2yOE4{OCEEsTC0Mlc2KG6P	M{DMTVI{QTZ{NES1
S1-M1-80	M1Xpbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn;kTWM2OD1{NkGuNFYhyrFiNEiuNlUhdk1?	M3TicVI{QTZ{NES1
CORL-23/P	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1HGUGlEPTB;ND6zPEDDuSBzLkK1JI5O	NUTBPZVrOjN7NkK0OFU>
CORL-23/R	NV[3UlJET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWTxfIxpUUN3ME21MlE3KMLzIEGuPFMhdk1?	NFLQNYIzOzl4MkS0OS=>
NIH3T3	M2GxSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUDJR\|UxRTRyLk[wJOKyKDRwOUegcm0>	M3q1XVI{QTZ{NES1
NIH3T3-G185	NYC1cI9KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX\nSXM4UUN3ME2yOFE{NjRyINMxJFQzOy54NjDuUS=>	Mmf1NlM6PjJ2NEW=
pcDNA-HEK293	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGPwPWVKSzVyPUKuO\|UhyrFiMD62O{BvVQ>?	NGfkW\|gzOzl4MkS0OS=>
MDR19-HEK293	Mn[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHzjTXdKSzVyPUi1MlUxKMLzIEGzMlY4KG6P	MoWzNlM6PjJ2NEW=
R482-HEK293	M2G0VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3fIW2lEPTB;MkWuPVchyrFiND65OUBvVQ>?	NGnjUnYzOzl4MkS0OS=>
MRP1-HEK293	NU\pcHZsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{n2cmlEPTB;Mj65PUDDuSBzLkS5JI5O	NGHPdJozOzl4MkS0OS=>
SF188	NXv5eWNsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYfFN41ZOTBvMUCwJI5O	MonPNlQuQTZiaB?=	NIDUbmlFVVOR	MU\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBkd26lZX70doF1cW:wLTDk[ZBm\GWwdDDtZY5v\XJ?	NVXueFJrOjN6OEe2OFU>
T98G	MoTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXKxNE0yODBibl2=	MUiyOE06PiCq	NULkZodPTE2VTx?=	NYjYcXpFcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZ49v[2WwdILheIlwdi1iZHXw[YRmdnRibXHucoVz	MYmyN\|g5PzZ2NR?=
DU145	Mn64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MonNSG1UVw>?	M4CyNGlEPTEkiMy2NEBvVQ>?	NVT5dHNYOjN6OES0Nlg>
LNCaP	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M133V2ROW09?	M4jBNmlEPTEkiMy3OUBvVQ>?	M3X4UVI{QDh2NEK4
PC3	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1qzfWROW09?	NIjXfYdKSzVy4pk8NVc2KG6P	M{\1eFI{QDh2NEK4
RT4	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV3hd5hpUUN3ME2yO{4zOSCwTR?=	Mmm2NlM4QTJ4M{m=
5637	MkDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYn2RYR4UUN3ME20OU41PyCwTR?=	M4S5eVI{Pzl{NkO5
T24	MoDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFrDbGNKSzVyPUe5MlEzKG6P	M{L5d\|I{Pzl{NkO5
MCF7	NUO1TWI1TnWwY4Tpc44hSXO\|YYm=	M1\keVExOCCwTR?=	NYXxdXltOSCq	MULEUXNQ	MYDy[YR2[2W\|IITo[UBqdmS3Y4Tpc44hd2cEoFfy[YIyNMLiU3frNUzDqFC\|Mj\|CpHNmenCrbnGzMEBidmUEoGfpd5Az	MWOyN\|c4ODJ2NB?=
KB-V1	Mn\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NITXTGFKSzVyPUOuPVIh\|ryP	MV:yN\|U6OzF7Nh?=
Hec50co	NUn1TJF[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIn0U3VKSzVyPUWgcm0>	MYCyN\|E1PjZ6Nx?=
MDA-MB-468	M2\2OGFxd3C2b4Ppd{BCe3OjeR?=	NX;FU3JEOS93L{GwJI5O	NVG0XmRIOjRxNEivO\|IhcA>?	NUHTfXZWTE2VTx?=	MmXVbY5lfWOnczDhdI9xfG:\|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	MVSyN\|E1PDJ7NB?=
MCF10A	M4XYTWFxd3C2b4Ppd{BCe3OjeR?=	Mo\xNU82NzFyIH7N	M1uwflI1NzR6L{eyJIg>	M4HXcWROW09?	Ml32bY5lfWOnczDhdI9xfG:\|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NXfPRopxOjNzNESyPVQ>
Huh-7	MkfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHLuOYoyNzFyL{GwNE8yODByIH7N	M4n1cVQ5KGh?		MU\k[YNz\WG\|ZYOgeIhmKGOnbHygeoli[mmuaYT5JIRwe2VvZHXw[Y5l\W62bIm=	M3r6TFIzPzR3NUi3
Daoy	NHXPdllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1vMO\|EvQDd3LUK0NEBvVQ>?	NUjNZYM3PzJiaB?=	MoXJSG1UVw>?	NXixTYJFUUN3ME21JI5O	MkKxNlI{QTB{N{m=
ONS-76	MlHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3TPNlEvQDd3LUK0NEBvVQ>?	MmfaO\|IhcA>?	NFvjU\|NFVVOR	M2HFdmlEPTB;Nz61JI5O	Mkf3NlI{QTB{N{m=
SUM 149	MnO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVuwMVExOCCwTR?=	NHjHbIo4OiCq		M2HD[olvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7hdi=>	NEPidmgzOjNyOUmzPS=>
MDA-MB-231	NXr3SHNvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjHe5l3OC1zMECgcm0>	NUn6XI5xPzJiaB?=		NEHjV4VqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7uZZI>	NHKxe3MzOjNyOUmzPS=>
HR5	M1jsV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVKwMVExOCCwTR?=	NYCwNWh4PzJiaB?=		NUXnb4FCcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoFz	M1XhWFIzOzB7OUO5
BT-474-M1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmPUNE0yODBibl2=	MWe3NkBp		MXjpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wYYK=	NXfQd\|BUOjJ\|MEm5N\|k>
AU565	NHKyNm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXezcVA{OC1zMECgcm0>	MmDXO\|IhcA>?		MXzpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wYYK=	NVrmN4pQOjJ\|MEm5N\|k>
T47D	Mnq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmnWNE0yODBibl2=	Mo\4O\|IhcA>?		M{iyWYlvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7hdi=>	NUi2fpRMOjJ\|MEm5N\|k>
MCF7	MmrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2fTTlAuOTByIH7N	NXXiVFVGPzJiaB?=		NYLNRWk4cW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoFz	MWmyNlMxQTl\|OR?=
HCT116p53(+/+)	MlntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2C5XlExNTFyMECgcm0>	NGLueXAzPC92ODDo		NV7rRo5KcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGOxbYDs[ZRmdHliYYSgNlUhdk1?	Mn;pNlIzPjJzN{G=
HCT116p53(-/-)	NFPL[IZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NULxVVJZOTBvMUCwNEBvVQ>?	M1LjdVI1NzR6IHi=		MVLpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36gZ49ueGyndHXsfUBifCB{NTDuUS=>	NYe2UYtxOjJ{NkKxO\|E>
HeLa	NXi3OZpUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHo[Y8yOC1zMECgcm0>	NY\Rc2xsPDhiaB?=	MXHEUXNQ	M3HlTWlEPTB;NUKuPUBvVQ>?	MmrXNlIxQDB{M{W=
HeLa	M2facWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXexNE0yODBibl2=	MkDsO\|IhcA>?	NFv6dHhFVVOR	M4[0dGlEPTB;NUCuOUBvVQ>?	NFfvSlAzOjB6MEKzOS=>
GBC	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVrBVpdCPzJiaB?=		Mn[xTWM2OD1zND63PEBvVQ>?	NV;MU4d3OjF7NkW3N\|k>
GB-CL-1	NHexNXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MX63NkBp		MUjJR\|UxRTVwMkKgcm0>	MX2yNVk3PTd\|OR?=
Mz-ChA-2	NX7mRVVDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M17JbFczKGh?		M1HoNmlEPTB;Mz6zNUBvVQ>?	MVuyNVk3PTd\|OR?=
TGBC1-TKB	NV;K[JBST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnnwNVQ1KGh?		MkO1TWM2OD14LkeyJI5O	NH7kVnUzOTl4NUezPS=>
Wittier	M1\Pemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2jCNlczKGh?		MVvJR\|UxRTNwMk[gcm0>	MnrPNlE6PjV5M{m=
H-1	NYX3fG9{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NV[1dJlFPzJiaB?=		MnHTTWM2OD17LkW0JI5O	NYLqbmtyOjF7NkW3N\|k>
HuH-28	MkC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{H0eVczKGh?		NGDqbm1KSzVyPUGxMlE6KG6P	NIHlZokzOTl4NUezPS=>
NEC	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NEnZZW04OiCq		Mn3sTWM2OD17Lkm4JI5O	M{P5ZVIyQTZ3N{O5
REB	MnLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXjKcGJJPzJiaB?=		NUDSRYpnUUN3ME2xN{42OSCwTR?=	M2rZbFIyQTZ3N{O5
CC-LP-1	NI\E[olIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFT2ZpM4OiCq		NEDBRnRKSzVyPUWuPFQhdk1?	MnXDNlE6PjV5M{m=
CC-SW-1	MmHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXu3NkBp		M165W2lEPTB;OT61OUBvVQ>?	Ml7qNlE6PjV5M{m=
EGI-1	M13Bdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVi3NkBp		NYDPZ3VtUUN3ME2xNE44OiCwTR?=	Mn\QNlE6PjV5M{m=
Sk-ChA-1	MoPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWq3NkBp		MV3JR\|UxRTF5LkKgcm0>	NYPTc4Q4OjF7NkW3N\|k>
TFK-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MYS3NkBp		NV;PSZJpUUN3ME2xN{41PSCwTR?=	MojhNlE6PjV5M{m=
786-O	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX\2cXoyPS16MDDuUS=>	NVH3UmtEQTZiaB?=	MoXDTGNt	Mnfhd5VxeHKnc4Pld{B1cGVicILvcIln\XKjdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkB4cXSqIFnDOVDDqH[jbIXld{Bw\iB{IITvJFIxKG6P	NIrRdJczOTZ2MkO3OC=>
A498	NV[4fmE1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnruOU05OCCwTR?=	NWnYVYJOQTZiaB?=	NGfwOJJJS2x?	NWTwdlZ{e3WycILld5NmeyC2aHWgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meiC5aYToJGlEPTEEoI\hcJVmeyCxZjCyJJRwKDJyIH7N	MV:yNVY1OjN5NB?=
ACHN	NEmzfGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYLJdYhjPS16MDDuUS=>	NXvvNYxsQTZiaB?=	NV3PZ5I{UEOu	MUnzeZBxemW\|c3XzJJRp\SCycn;sbYZmemG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJJdqfGhiSVO1NOKhfmGudXXzJI9nKDJidH:gNlAhdk1?	Mor6NlE3PDJ\|N{S=
Caki-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\UU4s4PS16MDDuUS=>	MoPQPVYhcA>?	MYXIR4w>	MYrzeZBxemW\|c3XzJJRp\SCycn;sbYZmemG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJJdqfGhiSVO1NOKhfmGudXXzJI9nKDJidH:gNlAhdk1?	MoLFNlE3PDJ\|N{S=
SN12C	M3H4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYG1MVgxKG6P	NUjWfmp3QTZiaB?=	NVG5WnNvUEOu	MmfCd5VxeHKnc4Pld{B1cGVicILvcIln\XKjdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkB4cXSqIFnDOVDDqH[jbIXld{Bw\iB{IITvJFIxKG6P	NEW3[ZYzOTZ2MkO3OC=>
HMC-1.1	Mn3GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVmxMVExODBibl2=	M4PFVVczKGh?		MXPpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoU>	MWiyNVI1OjF6OR?=
HMC-1.2	M{OxO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYGxMVExODBibl2=	NV\oSohGPzJiaB?=		MXnpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoU>	NFTaXmMzOTJ2MkG4PS=>
C2	M3npbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX74TmRyOS1zMECwJI5O	M3XmbFczKGh?		NGrjU5lqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmV?	NHnmWHozOTJ2MkG4PS=>
CHP-212	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVPjZYF4OS1zMkWgcm0>	NWjpeGpSOjRvMUKwJIg>		MkfjbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZR?=	NIrYSpkzOTF4OUK0Ni=>
IMR-32	NX\EfIdnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NILa[pQyNTF{NTDuUS=>	MlT3NlQuOTJyIHi=		MWnpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6n	M1fkcFIyOTZ7MkSy
Kelly	M17CNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE\WSHMyNTF{NTDuUS=>	MUKyOE0yOjBiaB?=		MlzmbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZR?=	M1TxSVIyOTZ7MkSy
SH-EP	NVvaelJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGrnW4gyNTF{NTDuUS=>	MnjHNlQuOTJyIHi=		NUfkXZJHcW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[S=>	NWX2dFRkOjFzNkmyOFI>
SH-SY5Y	MkOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmrONU0yOjVibl2=	MmXmNlQuOTJyIHi=		NHrUWWdqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7l	NF7GTZIzOTF4OUK0Ni=>
SK-N-AS	MlTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXKxMVEzPSCwTR?=	NVLNbHJ{OjRvMUKwJIg>		NIewfnFqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7l	M4DE[VIyOTZ7MkSy
SK-N-BE	NVzxOYZyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW[2fI5iOS1zMkWgcm0>	M16yOlI1NTF{MDDo		NUfWNHNjcW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[S=>	M1zv[\|IyOTZ7MkSy
KG1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnVXHJSOS9zMD:xNFAhdk1?	NFq3Z4k4OiCq	NYnuRZgzTE2VTx?=	MW\pcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6n	MlrRNVk1PTh\|NUi=
U937	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3n1VFEwOTBxMUCwJI5O	MUe3NkBp	MWTEUXNQ	NWXF[JJkcW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[S=>	M12zcFE6PDV6M{W4
CAL62	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVjaZYNJOC5zLUGwNEBvVQ>?	M4XoO\|czKGh?	NIq0PVBFVVOR	NHLzNZFGSzVyPUGuOEBvVQ>?	Mk\KNVkzOjN3NUO=
OCUT-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmPkNE4yNTFyMDDuUS=>	NYPGTHR5PzJiaB?=	MV\EUXNQ	NGTQVlZGSzVyPUKuN{BvVQ>?	MmL4NVkzOjN3NUO=
8505C	MlLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVXOVJlZOC5zLUGwNEBvVQ>?	MlvMO\|IhcA>?	NWfKdWM2TE2VTx?=	NIr4O\|dGSzVyPUOuNkBvVQ>?	MmTVNVkzOjN3NUO=
ACT-1	NEDOUm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2DGTlAvOS1zMECgcm0>	MkG5O\|IhcA>?	NV;Mb2l2TE2VTx?=	Mo\lSWM2OD13LkSgcm0>	MUCxPVIzOzV3Mx?=
SW1736	NEPTdolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mmj1NE4yNTFyMDDuUS=>	MnfVO\|IhcA>?	NIDa[HFFVVOR	Mn6zSWM2OD13Lk[gcm0>	M1jTZ\|E6OjJ\|NUWz

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pro-caspase-8 / cleaved caspase-8 / cleaved caspase-3 / cleaved caspase-9; PubMed: 27699933 Cancer Sci PLKi‐induced caspase activation. HeLa cells were treated with BI 2536 (10 nmol/L), BI 6727 (68 nmol/L), or GSK461364 (11 nmol/L), and HCT 116 cells were treated with BI 2536 (20 nmol/L), BI 6727 (70 nmol/L), or GSK461364 (12 nmol/L) for 48 h. The levels of cleaved caspase (CASP)‐3, ‐8, and ‐9 were examined by Western blot analysis. p-HH3 / PARP / Myc / p-Myc; PubMed: 24771642 Clin Cancer Res Western blotting showing more mitotic arrested (shown by phospho-histone H3) and apoptotic (shown by PARP) cells as well as lower MYC levels in LNCaP-Pim1 cells after BI 2536 treatment compared with LNCaP-Neo cells. The difference is obvious at lower dose of BI 2536 (10 nM). Both total MYC expression and phosphor-MYC levels were lower in Pim1 cells than Neo cells after BI 2536 treatment. pMEK / MEK / pERK / ERK / pRSK1 / RSK1; PubMed: 28430578 Oncotarget (A) and (B) Western blot analysis of the expression and activation of components of the MEK-ERK-RSK1 pathway in MKN45 and MKN74 cancer cells treated with BI 2536 and BI 6727 for 24 and 48 hours, respectively. pPlk1 / Plk1 / pMyt1; PubMed: 28430578 Oncotarget (A) and (B) Western blot analysis of the expression and phosphorylation of Plk1, and phosphorylation of Myt1 in the CSC-like and cancer cells after treatment with BI 2536 and BI 6727 for 24 and 48 hours, respectively. Aurora B / pAurora B / pAurora C / pH3 / Cyclin B1 / Securin / pBcl-XL / MPM2; PubMed: 25169932 Mol Oncol Western blot analysis of cells treated for 24 h with the indicated inhibitor concentrations. Cell lysates were immunoblotted for Plk1, Phospho-Aurora B (T232)/Aurora C (T198), Aurora B, histone H3 phosphorylated at S10 (pH3), Cdk1, Cyclin B1, Securin, Phospho-Bcl-XL, Induced myeloid leukemia cell differentiation protein Mcl-1, MPM-2 and β-Actin. Left (Hela cells); Right (HUVEC)	27699933 24771642 28430578 25169932
Immunofluorescence	p-H2AX / propidium iodide; PubMed: 22309939 Breast Cancer Res Apoptotic images of the cells after BI 2536 treatment, as revealed by HCS (high-content screening) instrument (×10) with phospho-H2AX antibody or PI (propidium iodide) intake. Pericentrin / α-tubulin; PubMed: 21772266 Nat Commun MEFs were labelled using Plk1, pericentrin and α-tubulin antibodies and 4,6-diamidino-2-phenylindole for the analysis by immunofluorescence microscopy. Representative examples of BI 2536-treated and control MEFs are depicted. Scale bar, 5 μm.	22309939 21772266
Growth inhibition assay	Cell viability; PubMed: 21772266 Nat Commun Proliferative activity of MEFs at different BI 2536 concentrations (25–250 nM; means±s.d., n=3, for each concentration). P<0.05, P<0.01, **P<0.001, Student's t-test, unpaired and two-tailed.	21772266

In vivo

BI 2536 given i.v. once or twice per week is highly efficacious in diverse xenograft models with acceptable tolerability by inhibiting cell proliferation through a mitotic arrest, and subsequently induction of tumor-cell death. Administration of BI 2536 at 50 mg/kg once or twice per week significantly inhibits growth of HCT 116 xenografts with T/C of 15% and 0.3%, respectively. BI 2536 treatment twice-weekly also leads to excellent tumor-growth in BxPC-3 and A549 models with T/C of 5% and 14%, respectively. ^[1]

Protocol

Kinase Assay:^[1]	- Collapse Plk1 in vitro kinase assay: Recombinant human Plk1 (residues 1-603) is expressed as N-terminal, GST-tagged fusion protein with a baculoviral expression system and purified by affinity chromatography with Glutathione-agarose. Enzyme activity assays for Plk1 are performed in the presence of serially diluted BI 2536 with 20 ng of recombinant kinase and 10 μg casein from bovine milk as the substrate. Kinase reactions are performed in a final volume of 60 μL for 45 minutes at 30 °C (15 mM MgCl₂, 25 mM MOPS [pH 7.0], 1 mM DTT, 1% DMSO, 7.5 mM ATP, 0.3 μCi γ-³³P-ATP). Reactions are terminated by the addition of 125 μL of ice-cold 5% TCA. After transfer of the precipitates to Multi-Screen mixed ester cellulose filter plates, plates are washed with 1% TCA and quantified radiometrically. Dose-response curve is used for calculating IC50 value.
Cell Research:^[1]	- Collapse Cell lines: HeLa, A43, SKOV-3, HT-29, K562, A549, Saos-2, MCF7, HCT116, COLO 205, Hep G2, Raji and PC-3 cells, etc. Concentrations: Dissolved in DMSO, final concentrations ~1 μM Incubation Time: 24 and 72 hours Method: Cells are exposed to various concentrations of BI 2536 for 24, and 72 hours. Cell growth is assessed by the measurement of Alamar Blue dye conversion in a fluorescence spectrophotometer. For determining the DNA content of the cultures, cell suspensions are fixed in 80% ethanol, treated for 5 minutes with 0.25% Triton X-100 in PBS, and incubated with 0.1% RNase and 10 μg/mL propidium iodide (PI) in PBS for 20 minutes at RT. Cell-cycle profiles are determined by flow cytometric analysis. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: Female BomTac:NMRI-Foxn1^nu mice injected subcutaneously with HCT 116, NCI-H460, or A549 cells Formulation: Formulated in hydrochloric acid (0.1 N), and diluted with 0.9% NaCl Dosages: ~50 mg/kg Administration: Injection i.v. once or twice per week (Only for Reference)

References

Solubility (25°C)

In vitro	Ethanol	100 mg/mL (191.69 mM)
	DMSO	21 mg/mL (40.25 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG 400+0.5% Tween 80+5% Propylene glycol For best results, use promptly after mixing.	15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download BI 2536 SDF

Molecular Weight	521.66
Formula	C₂₈H₃₉N₇O₃
CAS No.	755038-02-9
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02215044	Terminated	Drug: BI 2536 intravenous\|Drug: Gemcitabine intravenous	Pancreatic Neoplasms	Boehringer Ingelheim	June 2007	Phase 1
NCT02211833	Completed	Drug: BI 2536\|Drug: Pemetrexed	Carcinoma Non-Small-Cell Lung	Boehringer Ingelheim	October 2006	Phase 1
NCT00701766	Completed	Drug: BI 2536	Leukemia Myeloid Acute	Boehringer Ingelheim	October 2006	Phase 2
NCT00706498	Completed	Drug: BI 2536	Prostatic Neoplasms	Boehringer Ingelheim	September 2006	Phase 2
NCT00376623	Completed	Drug: BI 2536	Carcinoma Non-Small-Cell Lung	Boehringer Ingelheim	July 2006	Phase 2
NCT02211872	Completed	Drug: BI 2536 BS intravenous	Neoplasms	Boehringer Ingelheim	August 2004	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
We need to use BI 2536 in preclinical studies using mice, how to formulate the inhibitor for this in vivo study?
Answer:
For in vivo study, DMSO should not be more than 5% because the toxicity. You can formulated BI2536 in hydrochloric acid (0.1 N), and diluted with 0.9% NaCl for animal study according to the reference :( Supplemental Data) http://linkinghub.elsevier.com/retrieve/pii/S0960-9822(06)02671-6

PLK Signaling Pathway Map

PLK Inhibitors with Unique Features

Selective Plk Inhibitors

GSK461364 : Plk1-selective, K_i=2.2 nM.
Plk Inhibitor in Clinical Trial

Rigosertib (ON-01910) : Phase III for Myelo Dysplastic Syndrome (MDS).
Newest Plk Inhibitor

Ro3280 ^New : Potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3 nM.
Calssic Plk Inhibitor

Volasertib (BI 6727) : Highly potent Plk1 inhibitor with IC50 of 0.87 nM and in phase II trials.

Related PLK Products

SBE 13 HCl ^New

SBE 13 HCl is a potent and selective PLK1 inhibitor with IC50 of 200 pM, >4000-fold selectivity over Aurora A kinase, Plk2 and Plk3.
Ro-3306 ^New

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases.
CCG-1423 ^New

CCG-1423 is a specific RhoA pathway inhibitor, which inhibits SRF-mediated transcription.
Rigosertib (ON-01910)

Rigosertib (ON-01910) is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM in a cell-free assay. It shows 30-fold greater selectivity against Plk2 and no activity to Plk3. Phase 3.
HMN-214

HMN-214 is a prodrug of HMN-176, which alters the cellular spatial orientation of Plk1.
GSK461364

GSK461364 inhibits purified Plk1 with K_i of 2.2 nM in a cell-free assay. It is more than 1000-fold selective against Plk2/3. Phase 1.

Features:Demonstrates >390-fold selectivity for Plk1 relative to Plk2 and Plk3.
Volasertib (BI 6727)

Volasertib (BI 6727) is a highly potent Plk1 inhibitor with IC50 of 0.87 nM in a cell-free assay. It shows 6- and 65-fold greater selectivity against Plk2 and Plk3. Phase 3.

Features:A high volume of distribution, indicating good tissue penetration, and a long terminal half-life.
MLN0905

MLN0905 is a potent inhibitor of PLK1 with IC50 of 2 nM.
Ro3280

RO3280 is a potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3 nM.

Features:A selective PLK1 inhibitor. Demonstrates greater potency than BI2536. Potential use in nasopharyngeal carcinomas.
NMS-P937 (NMS1286937)

NMS-P937 (NMS1286937) is an orally available, selective Polo-like Kinase 1 (PLK1) inhibitor with IC50 of 2 nM, 5000-fold selectivity over PLK2/PLK3. Phase 1.

Choose Your Country or Region

By Signaling Pathways

By product type

BI 2536

Cited by 102 Publications

Purity & Quality Control

Choose Selective PLK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download BI 2536 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

PLK Signaling Pathway Map

PLK Inhibitors with Unique Features

Related PLK Products

Choose Your Country or Region

By Signaling Pathways

By product type

BI 2536

Cited by 102 Publications

Purity & Quality Control

Choose Selective PLK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download BI 2536 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

PLK Signaling Pathway Map

PLK Inhibitors with Unique Features

Related PLK Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)